We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,223

Eli Lilly’s Cialis patent withstands double patenting and utility challenges on appeal
  • Gowling WLG
  • Canada
  • April 26 2016

The Federal Court of Appeal has provided guidance on the law of obviousness-type double patenting in dismissing Mylan’s appeal pertaining to Eli


The SCC Monitor (19042016)
  • McCarthy Tétrault LLP
  • Canada
  • April 19 2016

The SCC recently granted leave to appeal from the judgment of the B.C. Court of Appeal in Douez v. Facebook (“Douez”), which likely garnered


Largest Patent Infringement Award in Canada Stands: Apotex Denied Leave to Appeal to the SCC
  • McCarthy Tétrault LLP
  • Canada
  • April 14 2016

Today, the Supreme Court of Canada denied Apotex’s final attempt at obtaining leave to appeal in the storied patent battle between Merck and Apotex


The TPP new rights for pharmaceutical patent holders in Canada
  • Gowling WLG
  • Canada
  • November 13 2015

The Canadian Government released the official consolidated text of the Trans-Pacific Partnership (TPP) agreement on Nov., 5, 2015. This follows the


Canadian Competition Bureau Releases Significant Updates to its IP Enforcement Guidelines
  • McCarthy Tétrault LLP
  • Canada
  • April 7 2016

On March 31, 2016, the Competition Bureau (Bureau) released revised Intellectual Property Enforcement Guidelines (IPEGs). These IPEGs reflect


Patent law: 2015 year in review
  • Gowling WLG
  • Canada
  • April 6 2016

A successful patentee in a patent infringement action is entitled to monetary compensation in relation to acts of infringement. In this regard, the


Gene Patents Remain Valid in Canada
  • Bereskin & Parr LLP
  • Canada
  • March 10 2016

The case involving a Children’s Hospital of Eastern Ontario (“CHEO”) challenge to an isolated gene patent has settled. For background on the case and


Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer


Federal Court of Appeal considers standard for “obvious to try” test
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 19 2016

On December 15, 2015, the Federal Court of Appeal confirmed that the correct standard for determining whether an invention is obvious under the


Rx IP Update: 2015 Highlights
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • January 4 2016

In November 2014, Apotex discontinued its appeal to the Supreme Court of Canada (SCC) on the eve of the hearing of its appeal regarding the validity